live program
TRANSCRIPT
Version 3 (Short)
TIME SATURDAY, MARCH 6, 2021 SUNDAY, MARCH 7, 2021
10:00 AM
EST
START
12:20 PM
EST
W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
(10:00 – 14:00)
Conveners: Serena S. Spudich and Nicolas Chomont
ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2
Frank Kirchhoff
ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY
Galit Alter
ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC
Jürgen Rockstroh
ADVANCES IN BIOMEDICAL PREVENTION OF HIV
Jean-Michel Molina
ADVANCES IN HIV CURE
Katherine J. Bar
OPENING SESSION (10:00 – 12:05)
CHAIRS WELCOME TO virtual CROI 2021
Chairs: Sharon L. Hillier, James A. Hoxie, and Elaine J. Abrams
MARTIN DELANEY PRESENTATION
INTRODUCTION
James Pickett
VACCINE NATIONALISM IS KILLING US: HOW INEQUITIES IN RESEARCH AND ACCESS TO SARS-CoV-2 VACCINES WILL PERPETUATE THE PANDEMIC
Gregg S. Gonsalves and Fatima Hassan
BERNARD FIELDS LECTURE
INTRODUCTION
James A. Hoxie and Galit Alter
NEUTRALIZING ANTIBODIES AGAINST CORONAVIRUSES
Pamela J. Bjorkman
N'GALY-MANN LECTURE
INTRODUCTION
Elaine J. Abrams and Tedros Adhanom Ghebreyesus
LESSONS FROM THE CONCURRENT HIV/AIDS AND COVID-19 PANDEMICS: A TWO-WAY STREET
Anthony S. Fauci
CONCURRENT WORKSHOPS (12:20 – 2:20)
W-2 FRONTIERS IN LABORATORY TECHNOLOGIES
Conveners: Galit Alter and Frank Kirchhoff
STRUCTURES OF SARS-CoV-2 ANTIBODIES INDUCED BY INFECTION AND mRNA VACCINES
Christopher O. Barnes
EMERGING CONCEPTS IN HIV-1 RESTRICTION
Edward Campbell
SARS-CoV-2 SPECIFIC AND CROSS-REACTIVE T CELL RESPONSES
Daniela Weiskopf
ARTIFICIAL INTELLIGENCE-INSPIRED ANTIBODY ENGINEERING
Sai Reddy
W-3 CLINICAL TRIAL DESIGN AND ANALYSIS
Conveners: Susan P. Buchbinder and Richard E. Chaisson
MAKING SENSE OF STUDY DESIGN DIFFERENCES BETWEEN COVID-19 PLATFORM TRIALS
Lori Dodd
DESIGN OF CURRENT AND FUTURE COVID-19 VACCINE EFFICACY TRIALS
Holly Janes
W-4 CASE TRACING AND CASE MANAGEMENT: COVID-19 WORKSHOP
Conveners: Robert T. Schooley and David L. Thomas
RAPID GENOMIC SEQUENCING FOR MANAGEMENT OF COVID-19
Kwok-Yung Yuen
COVID-19: A HOSPITALISED UNWELL PATIENT WITH PNEUMONITIS
Sanjay Bhagani
CRITICAL CARE OF COVID-19
Janhavi Athale
virtual CROI 2021 Schedule at a Glance LI
VE
PR
OG
RA
M
Last Updated on March 4, 2021
LIVE PROGRAM
LIVE PROGRAM
TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2021 WEDNESDAY, MARCH 10, 2021
10:00 AM EST
START
11:15 AM
EST
PLENARY SESSION (10:00 – 11:00)
Session Hosts: Wesley Sundquist and Carlos del Rio
WELCOME AND DAILY ROADMAP
Sharon L. Hillier
P-1 IMAGING VIRAL LIFE CYCLES
Hans-Georg Kräusslich
P-2 DISPARITIES IN HEALTH: FROM HIV TO COVID-19 AND BEYOND
James E. Hildreth
CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15)
O-1 HIV/SIV HOST AND CELLULAR INTERCTIONS: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS
Oral Abstract Moderators: John M. Coffin and Richard A. Koup
DECIPHERING THE HOST NUCLEUS SUBVERSION BY HIV-1 TO REPLICATE
Francesca Di Nunzio HIV-1 CAPSID RETAINS ITS INTEGRITY UNTIL MINUTES BEFORE UNCOATING IN THE NUCLEUS
Chenglei Li
TRAFFICKING OF HIV-1 ENVELOPE TO THE EHD1/MICAL-L1 TUBULAR-SORTING ENDOSOME
Paul Spearman
A COMPREHENSIVE CRISPR SCREEN FOR HIV DEPENDENCY FACTORS
Vanessa R. Montoya
EARLY bNAb THERAPY IN SHIVAD8-EO–INFECTED RHESUS MACAQUES
Joana Dias
IMMUNE CORRELATES OF POSTTREATMENT CONTROL IN SHIV-INFECTED INFANT MACAQUES
Veronica Obregon-Perko
SIV∆GY INFECTION INDUCES ELITE CONTROL AND RESISTANCE TO SHIV HETEROLOGOUS CHALLENGE
Susan Pereira Ribeiro
TRAPPING THE HIV-1 V3 LOOP IN A HELICAL CONFORMATION ENABLES BROAD NEUTRALIZATION Matthias Glögl
AN Env-gag mRNA VACCINE PROTECTS MACAQUES FROM HETEROLOGOUS TIER-2 SHIV INFECTION Peng Zhang
O-2 HIV TREATMENT AND PREVENTION: NEW OPPORTUNITIES TO OPTIMIZE DRUG DOSING, ADHERENCE, AND ANTIRETROVIRAL THERAPY
Oral Abstract Moderators: Angela Kashuba and Courtney V. Fletcher
ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP
Munjal Patel
NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS
Randolph P. Matthews
CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS
Justin Lutz
PK AND SAFETY OF HIGH-DOSE RIFAMPICIN IN TB/HIV COINFECTED PATIENTS ON EFV OR DTG
Christine Sekaggya-Wiltshire
PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH EFV-BASED ART IN ACTG 5375
Kimberly K. Scarsi
EMTRICITABINE TRIPHOSPHATE IN DRIED BLOOD SPOTS PREDICTS FUTURE VIREMIA IN PWH
Jose R. Castillo-Mancilla
TENOFOVIR DIPHOSPHATE TO PREDICT FUTURE VIRAEMIA IN POSTPARTUM WOMEN LIVING WITH HIV
Jasantha Odayar
NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: 48WKS PRIMARY OUTCOME
Nicholas Paton
RANDOMIZED TRIAL OF RESISTANCE TESTING FOR VIROLOGIC FAILURE IN SUB-SAHARAN AFRICA
Mark Siedner
O-3 COMPLICATIONS OF HIV AND COVID-19
Oral Abstract Moderators: Judith S. Currier and Peter W. Hunt
SHORT-COURSE ALENDRONATE FOR THE PREVENTION OF ART-ASSOCIATED BONE LOSS
Tara McGinty
PREVENTION OF CARDIOVASCULAR DISEASE IN PERSONS WITH AND WITHOUT HIV
Michael J. Silverberg
SEX MODIFIES THE ASSOCIATION BETWEEN INFLAMMATION AND VASCULAR EVENTS IN TREATED HIV
Samuel R. Schnittman
IDENTIFICATION OF UNIQUE PROTEINS PREDICTIVE OF MORTALITY AND MECHANISMS IN HIV
Priscilla Hsue
BIOLOGICAL PROFILES PREDICT CORONARY ARTERY DISEASE IN PWH AND RISK-MATCHED CONTROLS
Padraig McGettrick
12-YEAR COGNITIVE DECLINE IS ASSOCIATED WITH LUNG DISEASE, DIABETES, AND DEPRESSION
Scott Letendre
MULTIMORBIDITY IN PEOPLE WITH HIV USING ART IN THE US: PROJECTIONS TO 2030
Parastu Kasaie
COVID-19 HOSPITALIZATION AMONG PEOPLE WITH HIV OR SOLID ORGAN TRANSPLANT IN THE US
Jing Sun
O-4 IDENTIFYING DISPARITIES AND OPPORTUNITIES IN HIV
Oral Abstract Moderators: Richard E. Chaisson and Adaora Adimora
DISPARITIES IN TIMELY RECEIPT OF ART PRESCRIPTION IN HIV CARE IN THE US, 2012-2018
Jun Li
GEOGRAPHIC DIFFERENCES IN TIME TO VIRAL SUPPRESSION IN THE DEEP SOUTH, 2012-2019
Aadia Rana
DECREASED HIV DIAGNOSES AMONG MSM OF COLOR IN THRIVE-FUNDED JURISDICTIONS, 2014-2018
Kashif Iqbal
GENDER-AFFIRMING SURGERY ASSOCIATED WITH HIGH VIRAL SUPPRESSION AMONG TRANSGENDER PWH
Cristina Rodriguez-Hart
HIV TRENDS AMONG THE AMERICAN INDIAN/ALASKA NATIVES, 2014-2018
Sophie Sembajwe
LOWER UPTAKE OF DOLUTEGRAVIR AMONG WOMEN OF REPRODUCTIVE POTENTIAL VS MEN—KENYA
Matthew L. Romo
RCT OF AN ONLINE MENTAL HEALTH INTERVENTION AMONG OLDER PLWH DURING COVID-19 PANDEMIC
Peter Mazonson
FEE FOR HOME DELIVERY AND MONITORING OF ART RAISES VIRAL SUPPRESSION IN SOUTH AFRICA
Ruanne Barnabas
PLENARY SESSION (10:00 – 11:00)
Session Hosts: Peter W. Hunt and Sharon L. Hillier
WELCOME AND DAILY ROADMAP
Elaine J. Abrams
P-3 HIV-1 bNAbs: LOOKING AHEAD
Marina Caskey
P-4 SUSTAINED DELIVERY AND LONG-ACTING AGENTS FOR PREVENTION OF HIV
Linda-Gail Beker
CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15)
O-5 SARS-CoV-2 VS HOST: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS
Oral Abstract Moderators: Wesley I. Sundquist and Guido Silvestri
IFITM PROTEINS PROMOTE SARS-CoV-2 INFECTION IN HUMAN LUNG CELLS
Caterina Prelli Bozzo
SARBECOVIRUS ORF6 PROTEINS ANTAGONIZE INTERFERON SIGNALING
Izumi Kimura
SEVERE COVID-19 IS FUELED BY DISRUPTED GUT BARRIER INTEGRITY
Leila B. Giron
SARS-CoV-2 PERSISTS IN INTESTINAL ENTEROCYTES UP TO 7 MONTHS AFTER SYMPTOM RESOLUTION
Minami Tokuyama
COVID-19 OUTCOME: INSIGHTS FROM QUANTIFICATION OF VIREMIA AND NEUTRALIZING ANTIBODY
Jana L. Jacobs
CHARACTERIZATION AND EPITOPE MAPPING OF SARS-CoV-2–SPECIFIC T CELLS
Kristin L. Boswell
BARICITINIB LOWERS INFLAMMATION AND PATHOLOGY IN SARS-CoV-2–INFECTED RHESUS MACAQUES
Timothy Hoang
ONE DOSE OF COVID-19 mRNA VACCINE IN SARS-CoV-2–EXPERIENCED PEOPLE MAY BE SUFFICIENT
Mark Mulligan
SARS-CoV-2 RECRUITS A HAEM METABOLITE TO EVADE ANTIBODY IMMUNITY
Annachiara Rosa
O-6 NEW WEAPONS AGAINST SARS-CoV-2 AND HIV
Oral Abstract Moderators:
Joseph J. Eron and Douglas D. Richman
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING
Myron S. Cohen
BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS
Michael Dougan
CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS
Meagan P. O'Brien
POTENT NEUTRALIZING ANTIBODIES FOR SEVERE COVID-19: A RANDOMIZED CLINICAL TRIAL
Carlijn Jordans
ESTIMATING WITHIN-HOST R0 FOR SARS-CoV-2 AND IMPLICATIONS FOR ANTIVIRAL THERAPY
Ruian Ke
PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254
Christoph Spinner
POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH
Sorana Segal-Maurer
ACTIVITY AND RESISTANCE HARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR
Laurie VanderVeen
RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT
Tracy L. Diamond
O-7 TUBERCULOSIS AND HEPATITIS
Oral Abstract Moderators:
Constance A. Benson and Robert T. Schooley
RIFAPENTINE +/– MOXIFLOXACIN FOR PULMONARY TUBERCULOSIS IN PEOPLE WITH HIV
April Pettit
HIGH-DOSE RIFAMPICIN FOR HIV-ASSOCIATED TB MENINGITIS: A PHASE II RANDOMISED TRIAL
Fiona Cresswell
BICTEGRAVIR CONCENTRATIONS AND VIROLOGIC RESPONSES IN PLWH RECEIVING 1HP FOR LTBI
Hsin-Yun Sun
A CLUSTER RANDOMIZED TRIAL OF CONTACT TRACING IN HOUSEHOLDS OF INDEX PATIENTS WITH TB
Neil A. Martinson
A CLUSTER RANDOMIZED TRIAL OF TARGETED UNIVERSAL TESTING FOR TB IN CLINICS
Limakatso Lebina
A SIMPLE AND SAFE APPROACH TO HCV TREATMENT: FINDINGS FROM THE A5360 (MINMON) TRIAL
Sunil S. Solomon
HEPATOCELLULAR CARCINOMA AND HBV VIREMIA IN HIV/HBV-COINFECTED PERSONS IN NA-ACCORD
H. Nina Kim
UPRISING CIRCULATION OF HBV-COMPLEX PROFILES WITH HBsAg VACCINE-ESCAPE MUTATIONS
Lorenzo Piermatteo
O-8 COVID EPIDEMIOLOGY AND ITS IMPACT ON HIV CARE AND PREVENTION
Oral Abstract Moderators: Susan P. Buchbinder and James McIntyre
PHYLOGENETIC ANALYSIS OF THE TIMING OF SARS-CoV-2 INTRODUCTIONS INTO WASHINGTON STATE
Diana M. Tordoff
FROM TESTING TO MORTALITY: COVID-19 AND THE INVERSE CARE LAW IN SWITZERLAND
Julien Riou
SEX/GENDER DIFFERENCES IN TESTING, PRESENTATION, AND OUTCOMES OF SARS-CoV-2 INFECTION
Eileen P. Scully
RACIAL DISPARITIES IN COVID-19 POSITIVITY AMONG PEOPLE LIVING WITH HIV IN THE US
Jessica Y. Islam
HIV AND COVID-19 INPATIENT OUTCOMES: A MATCHED RETROSPECTIVE MULTICENTRE ANALYSIS
Ming J. Lee
CHANGES IN HIV TESTING SERVICES AFTER COVID-19 IN 11 SUB-SAHARAN AFRICAN COUNTRIES
Bakary Drammeh
DRAMATIC DECLINE IN PUBLIC SECTOR HIV/STI TESTING DURING SARS-CoV-2 PANDEMIC, OREGON
Timothy W. Menza
COVID-19 IMPACT ON INDEX TESTING SERVICES IN 5 HIGH HIV PREVALENCE INDIAN DISTRICTS
Ajay K. Enugu
O-9 PREVENTION 2021
Oral Abstract Moderators: Raphael J. Landovitz and Landon Myer
IMPACT OF VAGINAL STIs ON bNAb PROTECTION IN MACAQUES
David A. Garber
PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS
Albert Liu
INCIDENCE OF HIV INFECTION WITH DAILY OR ON-DEMAND ORAL PrEP WITH TDF/FTC IN FRANCE
Jean-Michel Molina
IMPACT OF COMMON SIDE EFFECTS ON PrEP PERSISTENCE DURING PREGNANCY IN SOUTH AFRICA
Dvora L. Joseph Davey
COST-EFFECTIVENESS OF LONG-ACTING PrEP AMONG MSM/TGW IN THE US
Anne M. Neilan
SOCIAL NETWORKS PREDICT PrEP UPTAKE IN SEARCH STUDY IN RURAL KENYA AND UGANDA
Catherine A. Koss
HSV-2 ACQUISITION IN A RANDOMIZED TRIAL OF CONTRACEPTIVE METHODS AMONG AFRICAN WOMEN
Nelly R. Mugo
LABORATORY ANALYSIS OF HIV INFECTIONS IN HPTN 083: INJECTABLE CAB FOR PrEP
Raphael J. Landovitz
PLENARY SESSION (10:00 – 11:00)
Session Hosts: Nicolas Chomont and Elaine J. Abrams
WELCOME AND DAILY ROADMAP
James A. Hoxie
P-5 ELITE CONTROLLERS: A MODEL FOR A FUNCTIONAL CURE OF HIV-1 INFECTION
Xu Yu
P-6 HIV TREATMENT IN PREGNANCY: BEYOND PREVENTION OF VERTICAL TRANSMISSION
Shahin Lockman
CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15)
O-10 HIV RESERVOIRS
Oral Abstract Moderators: Douglas D. Richman and Katharine J. Bar
INFECTED CELLS ARE CLONOTYPICALLY DIVERSE IN BLOOD & LYMPH NODES SINCE FIEBIG STAGE I Pierre Gantner
EVOLUTIONARY DYNAMICS OF HIV RESERVOIR CELLS VIA A NOVEL SINGLE-CELL MULTIOMICS ASSAY
Kevin B. Einkauf
NONINVASIVE PLASMA GLYCOMIC AND METABOLIC BIOMARKERS OF POSTTREATMENT HIV CONTROL
Leila B. Giron
PD-1 BLOCKADE ENHANCES THERAPEUTIC BENEFITS OF VACCINE IN A CHRONIC SIV/MACAQUE MODEL
Sheikh A. Rahman
TYPE I INTERFERON-ASSOCIATED GENE EXPRESSION PREDICTS TIME TO VIRAL REBOUND ON TI
Penny Zacharopoulou
HIV-1 PROVIRUS CANNOT BE REACTIVATED IN PATIENTS ON TREATMENT WITH ART AND DASATINIB
Mayte Coiras
DURABLE HIV-1 ANTIBODY PRODUCTION IN HUMANS AFTER AAV8-MEDIATED GENE TRANSFER
Joseph P. Casazza
A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION
Beatriz Mothe
O-11 BRAIN CONNECTIONS, MALIGNANCIES, AND TUMOR VIRUSES
Oral Abstract Moderators: Dennis L. Kolson and Ronald T. Mitsuyasu
NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART
Kazuo Suzuki
3T BRAIN MRS REVEALS DISTINCT METABOLITE PATTERNS OF ART INITIATION DURING ACUTE HIV
Napapon Sailasuta
EFFECTS OF HIV AND AGING ON FUNCTIONAL CONNECTIVITY AND ANATOMY
Patrick H. Luckett
DIVERGENT AND SELF-REACTIVE IMMUNE RESPONSES IN THE CNS OF COVID-19 PATIENTS
Shelli F. Farhadian
CHROMOSOMAL COPY NUMBER ALTERATIONS IN ANAL PRECANCERS FROM PEOPLE WITH HIV
Tinaye Mutetwa
POMALIDOMIDE AND LIPOSOMAL DOXORUBICIN FOR KAPOSI SARCOMA +/– OTHER KSHV DISEASES
Ramya Ramaswami
VAGINAL pH PREDICTS CERVICAL INTRAEPITHELIAL NEOPLASIA-2 REGRESSION IN HIV+ WOMEN
Katherine G. Michel
WILMS' TUMOR 1 IS OVEREXPRESSED IN KAPOSI SARCOMA AND IS REGULATED BY VFLIP/K13
Ayana Morales
INFLAMMASOME ACTIVATION IN PATIENTS WITH KSHV-ASSOCIATED DISORDERS
Ramya Ramaswami
O-12 MATERNAL AND CHILD HIV AND SARS-CoV-2
Oral Abstract Moderators: Landon Myer and Hermione Lyall
COVID-19 INFECTION IN HIGH-RISK SOUTH AFRICAN PREGNANCIES WITH AND WITHOUT HIV
Liesl De Waard
CHARACTERISATION OF SARS-CoV-2–INFECTED CHILDREN DEVELOPING NEUTRALISING ANTIBODIES
Alessandra Ruggiero
PEDIATRIC AND ADOLESCENT HIV TESTING AND DIAGNOSIS IN THE CONTEXT OF COVID-19
Jessica M. Gross
DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS
Anna Turkova
DolPHIN2 FINAL RESULTS DOLUTEGRAVIR VS EFAVIRENZ IN LATE PREGNANCY TO 72W POSTPARTUM
Thokozile R. Malaba
ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010
Risa M. Hoffman
SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL
Lameck Chinula
ADVERSE PREGNANCY OUTCOMES AMONG HIV-INFECTED WOMEN EXPOSED TO ISONIAZID IN BRIEF-TB
Amita Gupta
O-13 INNOVATIONS AND CHALLENGES IN TESTING, PREVENTION, AND CARE
Oral Abstract Moderators: Jonathan Mermin and Wafaa M. El-Sadr
PrEP USE DURING ACUTE HIV INFECTION IN A COMMUNITY SETTING COMPROMISES HIV DIAGNOSIS
Donn J. Colby
A CLUSTER-RANDOMIZED TRIAL OF TRADITIONAL HEALERS DELIVERING HIV TESTING IN UGANDA
Radhika Sundararajan
HIV SELF-TESTING TO OPTIMIZE FACILITY TESTING: A CLUSTER-RANDOMIZED TRIAL IN MALAWI
Kathryn Dovel
COMMUNITY MULTIMONTH ART PROVISION: POOLED ANALYSIS OF 2 CLUSTER-RANDOMIZED TRIALS
John Lopes
POINT-OF-CARE URINE TENOFOVIR VERSUS SELF-REPORTED ART ADHERENCE IN ROUTINE HIV CARE
Yolanda Gomba
RAPID VS SAME-DAY TREATMENT INITIATION FOR PATIENTS WITH TB SYMPTOMS AT HIV DIAGNOSIS
Nancy Dorvil
COMMUNITY DISTRIBUTION OF ART DURING CIVIL UNREST AND COVID-19 IN HAITI
Patrice Joseph
RESILIENCE OF HIV ACTIVITIES DURING COVID-19 PANDEMIC AT HEALTH FACILITIES IN AFRICA
Tiffany G. Harris
LIV
E P
RO
GR
AM
Last Updated on March 4, 2021
LIVE PROGRAM
LIVE PROGRAM
LIV
E P
RO
GR
AM
TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2020 WEDNESDAY, MARCH 10, 2020
1:30 PM EST
2:30 PM EST
END
CONCURRENT INTERACTIVE SESSIONS
(1:30 – 2:30)
I-1 SARS-CoV-2 EVOLUTION IN POPULATIONS AND INDIVIDUALS
Moderators: Katharine J. Bar and John Coffin
HIV-1 Env AND SARS-CoV-2 SPIKE EVOLUTION: SIMILARITIES AND DIFFERENCES
Bette Korber
SARS-CoV-2 EVOLUTION AT THE POPULATION LEVEL
Morgane Rolland
STRUCTURE AND FUNCTION OF SARS-CoV-2 SPIKE PROTEIN VARIANTS
Jeremy Luban
SELECTION OF NEUTRALIZATION RESISTANT SARS-CoV-2 MUTANTS
Paul Bieniasz
ANTIBODY IMMUNITY TO SARS-CoV-2 501Y.V2 THROUGH VACCINATION AND INFEC-TION
Penny Moore
I-2 CASE-BASED DISCUSSION ON WEIGHT GAIN IN HIV AND ANTIRETROVIRAL THERAPY
Moderator: Peter W. Hunt
Panelists: Grace McComsey, Sadaf Farooqi, Jane O’Halloran, and Cissy Kotyo
I-3 CONTACT TRACING IN CONTROLLING EPIDEMICS: IS THE JUICE WORTH THE SQUEEZE?
Moderator: Wafaa El-Sadr
THE ROLE OF CONTACT TRACING IN EPIDEMIC CONTROL: FACILITATORS AND BARRIERS Chi-Chi Udeagu
CONTACT TRACING FOR HIV AND SEXUALLY TRANSMITTED INFECTIONS Matthew Golden
CONTACT TRACING GOES VIRAL:VALUE AND ETHICS OF DIGITAL CONTACT TRACING
Jeffrey Khan
CONCURRENT INTERACTIVE SESSIONS
(1:30 – 2:30)
I-4 HIV-1 AND SARS-CoV-2: DURABILITY OF HOST IMMUNE RESPONSES FROM VACCINATION OR INFECTION
Moderators: Galit Alter and Guido Silvestri
HUMORAL RESPONSES AGAINST THE SARS-CoV-2 SPIKE
Andrés Finzi
T CELL IMMUNITY IN SARS-COV-2 NATURAL INFECTION AND FOLLOWING VACCINATION
Julie McElrath
LONGITUDINAL ANTIBODY RESPONSES TO SARS-CoV-2 AND EMERGING VARIANTS
Katie Doores
PROGRAMMING DURABLE IMMUNITY
Robert Seder
PATHOLOGICAL B CELL ACTIVATION DURING SARS-CoV-2 INFECTION
Ignacio Sanz
I-5 FROM DAILY PILLS TO MONTHLY SHOTS FOR HIV PREVENTION AND TREATMENT: CAN EFFICACY BE TRANSLATED INTO EFFECTIVENESS?
Moderators: Carlos del Rio and Diane Havlir
Panelists: Francois Venter,
Nittaya Phanuphak, Charles Flexner, and Hyman Scott
I-6 PrEP SCALE-UP TO MEET UNAIDS 2030 GOAL: IT JUST ISN'T POSSIBLE—OR IS IT?
SETTING THE STAGE: UNAIDS 2030 GOALS AND CURRENT STATE OF THE EPIDEMIC
Sheena McCormack
PrEP IMPLEMENTATION IN SUB-SAHARAN AFRICA
Elizabeth Irungu
CHALLENGES TO PrEP SCALE-UP
Mark Dybul
CONCURRENT INTERACTIVE SESSIONS
(1:30 – 2:30)
I-7 SARS-CoV-2 AND THE HOST IMMUNE RESPONSE: GOOD VS BAD IMMUNITY
Moderators: Richard A. Koup and
Nicolas Chomont
SARS-CoV-2 DEBRIS AND ITS CONTRIBUTION TO COVID-19
Benjamin tenOever
TOWARDS SWEET THERAPIES FOR SOUR IMMUNOPATHOLOGIES IN COVID-19
Catherine Blish
AFUCOSYLATED IgG RESPONSES AND SEVERITY IN COVID-19
Gestur Vidarsson
HUMORAL IMMUNE RESPONSES TO SARS-COV-2 (VIRSCAN)
Julie Overbaugh
THE SPECTRUM OF T CELL RESPONSES TO SARS-CoV-2
Marcus Buggert
I-8 COVID-19 CLINICAL CONTROVERSIES
Case Presenters and Discussion Moderators: Roy M. Gulick and Paul E. Sax
Panelists: Karine Lacombe, Zarir Udwadia, and Claudia Cortes
CASE 1: TREATMENT APPROACHES FOR A PATIENT WITH COVID-19 INFECTION
CASE 2: LONG-TERM OUTCOMES WITH A PATIENT WHO RECOVERS FROM COVID-19 INFECTION
I-9 COVID-19 DISPARITIES: HOW CAN THEY HELP MOVE THE NEEDLE FORWARD?
Moderators: Adaora Adimora and Monica Gandhi
DISPARITIES IN COVID-19 AMONG RACIAL AND ETHNIC MINORITIES IN THE US
Mary T. Bassett
DISPARITIES IN COVID-19 IN NATIVE AMERICAN COMMUNITIES
David R. Wilson
INCARCERATED POPULATIONS AND COVID-19
Robert E. Fullilove
Last Updated on March 4, 2021 LIVE PROGRAM
LIVE PROGRAM
ALL SCIENCE
SPOTLIGHTS™
ARE RELEASED
ON MARCH 6,
2021, AND ARE
AVAILABLE
THROUGHOUT
THE
CONFERENCE
BASIC SCIENCE (A-F)
A-1 VIROLOGY OF SARS-CoV-2
A-2 VIROLOGY OF HIV
B-1 ANIMAL MODELS FOR HIV INFECTION
B-2 HOST RESPONSE TO SARS-CoV-2
B-3 OUTCOMES OF SARS-CoV-2 INFECTION
B-4 HIV AND THE GUT MICROBIOME
B-5 NATURAL CONTROL OF HIV INFECTION
B-6 HOST EFFECTS ON HIV INFECTION
B-7 NON T-CELL EFFECTS OF HIV INFECTION
B-8 HIV AND T CELLS
B-9 HIV-CELL INTERACTION IN VIVO
D-1 EVOLUTION OF ANTIBODY RESPONSES TO SARS-CoV-2 INFECTION
D-2 CELLULAR IMMUNE RESPONSES TO SARS-CoV-2
D-3 NOVEL VACCINE CONCEPTS
D-4 NEUTRALIZING ANTIBODIES DURING INFECTION
D-5 THE IMPORTANCE OF TISSUE RESIDENCY
D-6 CHECKING OUT CHECKPOINTS
E-1 DYNAMICS OF THE HIV RESERVOIR
E-2 MECHANISMS OF HIV LATENCY
E-3 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL
REBOUND
E-4 HIV RESERVOIRS IN CELLS AND TISSUES
E-5 CONTROLLERS AND POSTTREATMENT CONTROLLERS
E-6 ASSAYS TO MEASURE AND CHARACTERIZE HIV PERSISTENCE
E-6 ASSAYS TO MEASURE AND CHARACTERIZE HIV PERSISTENCE
F-1 NEUROIMAGING AND ASSOCIATED BIOMARKERS
F-2 BIOMARKERS AND NEUROCOGNITIVE STATUS
F-3 COMORBIDITIES AND NEUROCOGNITIVE OUTCOMES
F-4 TREATMENT EFFECTS ON NEUROLOGIC OUTCOMES
F-5 CNS RESERVOIRS, ESCAPE, AND CONSEQUENCES
F-6 CNS AND PERIPHERAL NERVOUS SYSTEM: MODELS AND MARKERS OF
PATHOGENESIS
CLINICAL (G-Q)
G-1 ADVANCES IN ADHERENCE TESTING
G-2 EFFECTS OF DRUG DISPOSITION IN THE CSF, LYMPH NODES, LUNG, AND
GENITAL TRACT
G-3 DRUG-DRUG INTERACTIONS: FROM PREDICTIONS TO MANAGEMENT
G-4 NEW APPROACHES TO OPTIMIZE DRUG DOSING: LONG ACTING AND
BEYOND
H-1 NOVEL TREATMENTS FOR SARS-CoV-2: STARTING AT THE BENCH
H-2 SARS-CoV-2 TREATMENT: CLINICAL INTERVENTIONS
H-3 ANTIRETROVIRAL THERAPY IN THE DEVELOPING WORLD
H-4 LONG-ACTING THERAPY: THE TIME HAS COME
H-5 ANTIRETROVIRAL THERAPY: INSIGHTS FROM OBSERVATIONAL STUDIES
H-6 CLINICAL TRIALS OF ANTIRETROVIRAL THERAPY: TREATMENT NAIVE
AND SWITCH
I-1 NEW DRUGS, OLD DRUGS, AND NEW RESISTANCE MECHANISMS
I-2 NEW DEVELOPMENTS IN TRANSMITTED AND ACQUIRED DRUG
RESISTANCE
I-3 NEW RESISTANCE TECHNOLOGIES: ADVANTAGES AND LIMITATIONS
J-1 HCV: THERAPEUTICS AND PROGRESS TOWARD ELIMINATION
J-2 HEPATITIS B: NO LONGER PLAN B
J-3 MECHANISMS OF HEPATIC INJURY
J-4 HEPATITIS A AND D
J-5 HEPATITIS AND LIVER TRANSPLANTATION
K1,C1 CANCER: ANAL CANCER AND HPV
K-2 CANCER: KAPOSI SARCOMA & KAPOSI SARCOMA–ASSOCIATED
HERPESVIRUS, CERVICAL, LUNG, BREAST, LYMPHOMA, AND HEAD &
NECK
K-3 CANCER: RISK, EPIDEMIOLOGY, AND CARE
L-1 BIOMARKERS OF INFLAMMATION, ART, AND ATHEROSCLEROSIS OR
CARDIOVASCULAR DISEASE
L-2 GLOBAL STUDIES OF CARDIOVASCULAR DISEASE IN HIV
L-3 NOVEL INSIGHTS IN HIV AND CARDIOVASCULAR DISEASE
M-1 WEIGHT GAIN DURING ART
M-2 TYPE 2 DIABETES DURING ART
M-3 EPIDEMIOLOGY OF COMORBIDITIES
M-4 INFLAMMATION AND COMORBIDITIES DURING ART
M-5 FRAILTY AND FUNCTIONAL STATUS
M-6 RENAL AND BONE DISEASES
N-1 WHEN VIRUSES COLLIDE: HIV AND SARS-CoV-2
N-2 SARS-CoV-2: MORE THAN A RESPIRATORY VIRUS
O-1 TUBERCULOSIS SCREENING AND DETECTION
O-2 TUBERCULOSIS PREVENTION AND TREATMENT
O-3 CRYPTOCOCCAL MENINGITIS DETECTION AND OUTCOMES
P-1 MATERNAL VIRAL LOAD AND ART ADHERENCE: INSIGHTS AND
INTERVENTIONS
P-2 CHRONIC COMORBIDITIES IN PREGNANT WOMEN WITH HIV
P-3 UNDERSTANDING AND IMPROVING PREGNANCY OUTCOMES
P-4 EVOLVING INSIGHTS INTO PMTCT SERVICES
Q-1 HEALTH OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN AND
YOUTH
Q-2 CHARACTERIZING THE VIRAL RESERVOIR AND IMMUNE RESPONSE IN
PEDIATRIC HIV INFECTION
Q-3 ARVs AND bNAbs FOR CHILDREN AND ADOLESCENTS
Q-4 COMPLICATIONS AND MORTALITY IN CHILDREN AND YOUTH
Q-5 COVID-19 IN CHILDREN
EPIDEMIOLOGY/PUBLIC HEALTH (R-Y)
R-1 COVID-19 EPIDEMIOLOGY
R-2 HIV EPIDEMIOLOGY
R-3 GEOGRAPHIC AND PHYLOGENETIC TRANSMISSION DYNAMICS
R-4 DISPARITIES AND STRUCTURAL FACTORS AFFECTING HIV CARE
OUTCOMES
R-5 STIGMA, MENTAL HEALTH, AND SUBSTANCE USE: IMPACT ON
OUTCOMES
R-6 MODELING HIV OUTCOMES
T-1 RAPID HIV TESTING AND SELF TESTING
T-2 RECENCY ASSAYS AND INCIDENCE ESTIMATION
T-3 ROUTINE HIV TESTING
T-4 SARS-CoV-2 TESTING AND EFFECT OF COVID-19 ON HIV SCREENING
V-1 LESSONS AND CHALLENGES IN ORAL PrEP IMPLEMENTATION
V-2 PrEP ADHERENCE AND CONTROL OF STIs
V-3 NEW PrEP AGENTS AND FORMULATIONS
V-4 HIV PREVENTION: CIRCUMCISION AND IDUs
X-1 REPRODUCTIVE HEALTH AMONG ADOLESCENTS AT RISK OF HIV
X-2 EPIDEMIOLOGY OF SYPHILIS AND HIV COINFECTION: THE MORE THINGS
CHANGE…
X-3 ISSUES IN HIV AND WOMEN'S REPRODUCTIVE HEALTH
Y-1 EFFECT OF COVID-19 ON HIV SERVICES
Y-2 THE HIV CARE CASCADE
Y-3 DIFFERENTIATED SERVICE DELIVERY
Y-4 PREEXPOSURE PROPHYLAXIS
Y-5 KEY POPULATIONS
TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2020 WEDNESDAY, MARCH 10, 2020
SYMPOSIA ARE
RELEASED EACH
DAY AT 12:01
AM EST
ON-DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM)
S-1 NAVIGATING TO THE NUCLEUS
Conveners: John M. Coffin and Wesley I. Sundquist
LIVE-CELL IMAGING: CAPSID TRAFFICKING TO THE NUCLEUS
Barbara Müller
LIVE-CELL IMAGING OF HIV-1 NUCLEAR IMPORT, UNCOATING, AND PROVIRUSES
Vanay K. Pathak
VISUALIZATION OF HIV-1 CAPSID-DEPENDENT REPLICATION IN VITRO
Barbie Ganser-Pornillos
LENACAPAVIR (GS-6207): FIRST CLINICALLY ACTIVE LONG-ACTING INHIBITOR OF HIV CAPSID
Tomas Cihlar
S-2 INNATE IMMUNE DEFENSES AGAINST HIV-1 AND SARS-CoV-2
Conveners: Galit Alter and Frank Kirchhoff
FROM GENOME TO FUNCTION: PHENOTYPIC CHARACTERISATION OF PANDEMIC SARS-CoV-2 VARIANTS
Volker Thiel
IMMUNE EVASION STRATEGIES BY SARS-CoV-2: Nsp1 AND BEYOND
Konstantin Sparrer
SHARED VULNERABILITIES AND DIFFERENT COUNTERMEASURES OF HIV AND SARS-CoV-2
Eric O. Freed
IMMUNE RESPONSES TO SARS-CoV-2
Akiko Iwasaki
S-3 TUBERCULOSIS: NEW APPROACHES TO PREVENTION AND TREATMENT AND ISSUES FOR PREGNANT WOMEN AND CHILDREN
Conveners: Constance A. Benson and Richard E. Chaisson
THE POTENTIAL OF LONG-ACTING INJECTABLE DRUGS FOR PREVENTION AND TREATMENT OF TUBERCULOSIS
Eric Nuermberger
PREGNANCY, HIV, AND TUBERCULOSIS: CURRENT PRACTICES AND RESEARCH OPPORTUNITIES
Jyoti S. Mathad
ADVANCES IN PEDIATRIC TUBERCULOSIS PREVENTION AND TREATMENT
Nicole Salazar-Austin
IMPACT OF COVID-19 PANDEMIC ON HIV AND TUBERCULOSIS: WHO PERSPECTIVE
Souyma Swaminathan
S-4 EFFECT OF HIV ON COVID, EFFECT OF COVID ON HIV
Conveners: François Dabis and Wafaa M. El-Sadr
DOES HIV IMPACT COVID-19 SUSCEPTIBILITY OR SEVERITY?
Julia Del Amo
THE IMPACT OF COVID-19 ON THE HIV PANDEMIC WORLDWIDE
Andrew D. Kambugu
THE IMPACT OF COVID-19 BEYOND HIV
Helen Bygrave
FEAR AND COVID-19: EXPERIENCES ON THE GROUND
Francois Venter
ON-DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM)
S-5 IMMUNE-MEDIATING KILLING OF HIV RESERVOIRS: OPPORTUNITIES AND OBSTACLES
Conveners: Nicolas Chomont and Katharine J. Bar
HOW TO GENERATE GOOD KILLERS BY INITIATING ART (NOT TOO) EARLY?
Mark Dybul
BREAKING THE B-CELL FOLLICLE BARRIER TO ELIMINATE VIRAL RESERVOIRS
Afam Okoye
INTRINSIC RESISTANCE OF RESERVOIR CELLS TO IMMUNE KILLING
R. Brad Jones
TYPE I INTERFERON RESISTANCE OF REBOUND HIV-1
Beatrice H. Hahn
S-6 NOVEL ANTIVIRAL STRATEGIES AND HOW TO DEPLOY THEM
Conveners: Joseph J. Eron and Huldrych F. Günthard
TRIPLE DRUG ART, DUAL ART, OR JUST ART?
Jose R. Arribas
NOVEL ANTIRETROVIRAL THERAPIES IN CLINICAL DEVELOPMENT
Alexandra L. Calmy
ARVs AND ART FOR NEWBORNS AND INFANTS: A LAST FRONTIER
Moherndran Archary
GOT ANYTHING FOR THIS COUGH? NEW ANTIVIRALS FOR TREATMENT OF SARS-CoV-2
Davey M. Smith
S-7 COVID-19: FAR MORE THAN JUST THE LUNGS
Conveners: Serena S. Spudich and Peter Reiss
SINGLE VASCULAR CELL HETEROGENEITY IN HEALTH AND DISEASE: A COVID-19 UPDATE
Peter Carmeliet
BODY ON FIRE: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN
Elizabeth A. Whittaker
THINK ABOUT IT: NEUROLOGIC MANIFESTATIONS OF COVID-19
Benedict D. Michael
COVID-19: CONCERNS OF THE HEART
Valentina O. Puntmann
S-8 WHAT DOES PrEP DELIVER?
Conveners: Connie L. Celum and Monica Gandhi
YOUNG WOMEN: ADHERENCE, EFFECT, AND RETENTION
Thesla Palanee-Phillips
CHALLENGES AND OPPORTUNITIES IN IMPLEMENTING PrEP IN KEY POPULATIONS
Gregorio A. Millett
MODELS OF DELIVERING PrEP IN EAST AFRICA: INNOVATIONS AND LESSONS LEARNED
Moses R. Kamya
INCORPORATING INJECTABLE PrEP AND NEWER FORMULATIONS INTO LMIC
Yogan Pillay
ON-DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM)
S-9 NEW FINDINGS AND UNSETTLED CONTROVERSIES IN CENTRAL NERVOUS SYSTEM INFECTION AND DISEASE
Conveners: Dennis L. Kolson and Serena S. Spudich
NOVEL FINDINGS OF NEURONAL MODULATION OF HIV EXPRESSION IN MICROGLIA
Jonathan Karn
ROLE OF CNS CD4 T CELLS AND MACROPHAGES IN SIV NEUROPATHOGENESIS AND RESERVOIRS
Vanessa M. Hirsch
MYELOID CNS HIV RESERVOIRS...THE DEBATE CONTINUES
Lishomwa Ndhlovu
LESSONS FROM CNS HIV ESCAPE AND ATI FOR UNDERSTANDING HIV PERSISTENCE IN THE CNS
Sarah B. Joseph
S-10 ADOLESCENTS, YOUTH, AND PrEP
Conveners: Annette H. Sohn and Connie L. Celum
PrEP DURING PREGNANCY AND BREASTFEEDING
John Kinuthia
IMPROVING ADOLESCENT PrEP USE: UNDERSTANDING DEVELOPMENTAL PROCESSES AND CONTEXT
Claude A. Mellins
PrEP ADHERENCE INTERVENTIONS FOR ADOLESCENTS AND YOUNG ADULTS
Sybil Hosek
IMPROVING HOW WE MARKET PrEP TO YOUTH
Elzette Rousseau
S-11 FOCUS ON THE LIVER: NEW INSIGHTS INTO MANAGEMENT AND CONTROL OF LIVER DISEASE
Conveners: David L. Thomas and Jürgen K. Rockstroh
HEPATITIS C ELIMINATION: WHAT'S TAKING SO LONG?
Annie Luetkemeyer
MECHANISMS AND TREATMENTS OF STEATOSIS IN HIV
Steven Grinspoon
HARNESSING IMMUNITY TO CURE HBV
Ulrike Protzer
NEW PROSPECTS FOR THE TREATMENT OF HBV
Heiner Wedemeyer
S-12 COVID-19 VACCINE: FROM EFFICACY TO EFFECTIVENESS
Conveners: Susan P. Buchbinder and Carlos del Rio
LESSONS LEARNED AND CHALLENGES IN COVID-19 VACCINE TRIALS
Kathleen Neuzil
EQUITABLE ROLL-OUT OF COVID-19 VACCINES IN THE UNITED STATES
Michelle A. Williams
VACCINE ACCEPTANCE
Saad Omer
GLOBAL DISTRIBUTION OF THE SARS-CoV-2 VACCINE
Nicole Lurie
Last Updated on March 4, 2021
ON
-DEM
AN
D P
RO
GR
AM
ON-DEMAND PROGRAM
ON-DEMAND PROGRAM